From Diagnosis to Infrastructure: The System-Level Transformation of Alzheimer’s Disease

 📊 From Diagnosis to Infrastructure: The System-Level Transformation of Alzheimer’s Disease

Author: KJ Lavan

⸻

Executive Summary

Alzheimer’s disease is undergoing a structural transition from a symptom-based neurological condition to a biologically defined, system-managed disease.

Three converging domains—therapeutics, biomarkers, and diagnostics—are reshaping not only clinical care, but also the economic and policy architecture of ageing societies.

This transition introduces a new paradigm:

Alzheimer’s is no longer defined solely by cognitive decline, but by measurable biological signals that determine access to intervention.

Recent advances including disease-modifying therapies, blood-based biomarkers, and scalable diagnostic pathways—are accelerating this shift toward earlier detection and interventionAlzheimer’s Association (2025).

⸻

1. Therapeutics: From Validation to Optimization

The approval and expansion of anti-amyloid therapies developed by Eli Lilly (donanemab) and Eisai / Biogen (lecanemab) mark a turning point in disease-modifying treatment.

Clinical trials demonstrate that:

• Amyloid-targeting therapies can slow cognitive decline in early-stage Alzheimer’s disease
• Treatment efficacy is stage-dependent, with earlier intervention yielding greater benefit
• Safety considerations (e.g., ARIA) and delivery constraints affect scalability

(New England Journal of Medicine, 2022–2023; U.S. Food and Drug Administration, 2023–2025)

The therapeutic pipeline is expanding beyond amyloid to include:

• Tau-targeting therapies (e.g., Bristol Myers Squibb / Prothena)
• Oligomer-specific approaches (e.g., Acumen Pharmaceuticals)
• Genotype-driven precision medicine (e.g., Alzheon)

Implication:

Therapeutics are transitioning from proof-of-concept to precision deployment, requiring integration with biomarker and diagnostic systems.

⸻

2. Biomarkers: The Emergence of a Decision Layer

Blood-based biomarkers—particularly plasma phosphorylated tau (p-tau217)—are rapidly becoming central to Alzheimer’s detection and management.

According to the Alzheimer’s Association Clinical Practice Guidelines (AAIC 2025):

• Blood biomarkers are approaching routine clinical use in specialty care settings
• Multi-analyte panels improve diagnostic accuracy and disease staging
• Biomarkers are increasingly used to determine eligibility for disease-modifying therapies

(Alzheimer’s Association, 2025)

Industry leaders advancing this space include:

• Quanterix (ultra-sensitive detection platforms)
• Roche Diagnostics (integrated immunoassay platforms)
• ALZpath (p-tau217 assay standardization)

Emerging evidence suggests that multi-marker panels (e.g., p-tau217, Aβ42/40, GFAP, NfL) significantly improve predictive accuracy compared to single biomarkers

(Ashton et al., Nature Medicine, 2023).

Implication:

Biomarkers are evolving into a clinical and economic control layer, determining:

• Who qualifies for treatment
• When intervention occurs
• How disease progression is monitored

⸻

3. Diagnostics: From Bottleneck to Scalable Access

Historically, Alzheimer’s diagnosis relied on:

• Amyloid PET imaging
• Cerebrospinal fluid (CSF) analysis

While accurate, these approaches are resource-intensive and inaccessible at population scale.

Recent advancements include:

• FDA-cleared blood-based diagnostics from Fujirebio (plasma pTau217/Aβ ratio)
• Primary-care rule-out tools from Roche (Elecsys platform)
• AI-enabled imaging and quantification via Siemens Healthineers

(U.S. Food and Drug Administration, 2025; Siemens Healthineers, 2025)

In parallel, digital tools are emerging as a front-door screening layer:

• Altoida (AI/AR cognitive assessment)
• Cogstate (validated digital cognitive testing)

These tools enable continuous, low-friction monitoring outside clinical settings.

Implication:

Diagnostics are transitioning toward a tiered, scalable system architecture:

1. Digital screening (population level)
2. Blood-based biomarker triage
3. Imaging confirmation
4. Therapeutic pathway entry

⸻

4. System-Level Implications

The convergence of therapeutics, biomarkers, and diagnostics creates a new operating model:

Layer	Function
Therapeutics	Intervention
Biomarkers	Decision / eligibility
Diagnostics	Access / system entry

This architecture introduces critical system challenges:

• Access inequality: early detection determines treatment eligibility
• Reimbursement misalignment: fragmented payment across layers
• Workforce gaps: limited primary care readiness for early detection
• Data fragmentation: lack of longitudinal monitoring infrastructure

From a macroeconomic perspective, dementia already costs the global economy approximately $1.3 trillion annually, projected to reach $2.8 trillion by 2030

(World Health Organization, 2023).

⸻

5. Policy Recommendations

To align health systems with this emerging paradigm:

1. Establish National Biomarker Strategies

• Standardize clinical use of blood-based biomarkers
• Integrate into reimbursement frameworks

2. Expand Primary Care Capacity

• Train clinicians in early detection pathways
• Deploy scalable diagnostic tools

3. Incentivize Early Intervention

• Shift reimbursement toward prevention and early-stage care
• Align incentives with long-term economic outcomes

4. Build Brain Health Infrastructure

• Treat brain health as economic infrastructure, not solely healthcare
• Integrate into national productivity and ageing strategies

⸻

Conclusion

Alzheimer’s disease is transitioning from a clinical diagnosis to a system-level infrastructure challenge.

The next phase of progress will not be defined by a single breakthrough.

But by how effectively health systems integrate:

→ Therapeutics (intervention)

→ Biomarkers (decision-making)

→ Diagnostics (access pathways)

…into a coherent, scalable architecture of care.

⸻

📚 References

1. Alzheimer’s Association. Clinical Practice Guideline for Blood-Based Biomarkers. AAIC 2025.

2. New England Journal of Medicine. Van Dyck et al. (2023). Lecanemab in Early Alzheimer’s Disease.

3. New England Journal of Medicine. Mintun et al. (2021/2023 updates). Donanemab in Early Alzheimer’s Disease.

4. U.S. Food and Drug Administration. Drug approvals and diagnostic clearances (2023–2025).

5. Ashton et al. (2023). Plasma p-tau217 accuracy in Alzheimer’s disease. Nature Medicine.

6. World Health Organization. Global Status Report on Dementia (2023).

7. Siemens Healthineers (2025). AI-enabled neuroimaging quantification advancements.

8. Fujirebio (2025). Plasma biomarker diagnostic clearance announcements.

9. Roche Diagnostics (2024–2025). Elecsys Alzheimer’s biomarker platform updates.

Author: KJ Lavan